High School Seniors Smoking Less in 1998

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

WASHINGTON-Daily cigarette smoking among high school seniors declined in 1998, down to 22.4% from 24.6% in 1997. However, the 1998 rate remains significantly higher than the 17.2% recorded in 1992 and not far removed from the 25.4% found in 1979, according to a survey conducted for the National Institute on Drug Abuse.

WASHINGTON—Daily cigarette smoking among high school seniors declined in 1998, down to 22.4% from 24.6% in 1997. However, the 1998 rate remains significantly higher than the 17.2% recorded in 1992 and not far removed from the 25.4% found in 1979, according to a survey conducted for the National Institute on Drug Abuse.

The study found that the percentage of 12th graders who smoked at least a half-pack per day dropped to 12.6% in 1998, from 14.3% in 1997. Black students had the lowest smoking rates for the year, with 12.6% reporting some smoking in the month prior to the survey, compared with 41.7% of whites and 26.6% of Hispanics.

The statistics were compiled as part of Monitoring the Future, an annual survey of teen substance abuse conducted since 1975 by the University of Michigan’s Institute for Social Research.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content